Flaws in the trial design of IFCT-0802

Ann Oncol. 2015 Sep;26(9):2003. doi: 10.1093/annonc/mdv273. Epub 2015 Jun 25.

Authors

B Gyawali¹, T Shimokata², K Honda², Y Ando²

Affiliations

¹ Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan. Electronic address: bg.bishalgyawali@gmail.com.
² Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.

PMID: 26113649
DOI: 10.1093/annonc/mdv273

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Angiogenesis Inhibitors / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bevacizumab / therapeutic use*
Female
Humans
Lung Neoplasms / drug therapy*
Male
Small Cell Lung Carcinoma / drug therapy*

Substances

Angiogenesis Inhibitors
Bevacizumab